6533b85efe1ef96bd12bfe6c
RESEARCH PRODUCT
Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double-Blind Primary Endpoint.
Alfons SchnitzlerPablo MirMatthew A. BrodskyLeonard VerhagenSergiu GroppaRamiro AlvarezAndrew EvansMarta BlazquezSean NagelJulie G. PilitsisMonika Pötter-nergerWinona TseLeonardo AlmeidaNestor TomyczJoohi Jimenez-shahedWitold LibionkaFatima CarrilloChristian J. HartmannStefan Jun GroissMartin GlaserFlorence DefresneEdward KarstBinith CheeranJan VesperAlfons SchnitzlerJan VesperPablo MirLeonardo VerhagenNestor TomcyzChristian J. HartmannSergiu GroppaRamiro AlvarezJulie PilitsisMonika Pötter-nergerStefan Jun GroissMatthew A. Brodskysubject
MaleDeep brain stimulationParkinson's diseasemedicine.medical_treatmentParkinson's diseaseDeep Brain StimulationStimulation03 medical and health sciences0302 clinical medicinemedicineClinical endpointHumanstherapeutic windowNeurostimulationTherapeutic windowCross-Over Studiesbusiness.industrydirectional programmingParkinson DiseaseGeneral Medicinemedicine.diseaseCrossover studySubthalamic nucleusAnesthesiology and Pain MedicineTreatment OutcomeNeurologyAnesthesiaQuality of LifeFemaleNeurology (clinical)business030217 neurology & neurosurgerydescription
Objective Published reports on directional deep brain stimulation (DBS) have been limited to small, single-center investigations. Therapeutic window (TW) is used to describe the range of stimulation amplitudes achieving symptom relief without side effects. This crossover study performed a randomized double-blind assessment of TW for directional and omnidirectional DBS in a large cohort of patients implanted with a DBS system in the subthalamic nucleus for Parkinson's disease. Materials and methods Participants received omnidirectional stimulation for the first three months after initial study programming, followed by directional DBS for the following three months. The primary endpoint was a double-blind, randomized evaluation of TW for directional vs. omnidirectional stimulation at three months after initial study programming. Additional data recorded at three- and six-month follow-ups included stimulation preference, therapeutic current strength, Unified Parkinson's Disease Rating Scale (UPDRS) part III motor score, and quality of life. Results The study enrolled 234 subjects (62 ± 8 years, 33% female). TW was wider using directional stimulation in 183 of 202 subjects (90.6%). The mean increase in TW with directional stimulation was 41% (2.98 ± 1.38 mA, compared to 2.11 ± 1.33 mA for omnidirectional). UPDRS part III motor score on medication improved 42.4% at three months (after three months of omnidirectional stimulation) and 43.3% at six months (after three months of directional stimulation) with stimulation on, compared to stimulation off. After six months, 52.8% of subjects blinded to stimulation type (102/193) preferred the period with directional stimulation, and 25.9% (50/193) preferred the omnidirectional period. The directional period was preferred by 58.5% of clinicians (113/193) vs. 21.2% (41/193) who preferred the omnidirectional period. Conclusion Directional stimulation yielded a wider TW compared to omnidirectional stimulation and was preferred by blinded subjects and clinicians.
year | journal | country | edition | language |
---|---|---|---|---|
2022-08-01 |